Europe Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report, By Derived Cell; By Workflow (Reprogramming, Cell Culture, Cell Characterization, Engineering, Others); By Application; By Country; Segment Forecast, 2024 - 2032
- Published Date:May-2024
- Pages: 116
- Format: PDF
- Report ID: PM4903
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
Europe Induced Pluripotent Stem Cell (iPSC) market size was valued at USD 500.62 million in 2023. The market is anticipated to grow from USD 546.24 million in 2024 to USD 1,111.97 million by 2032, exhibiting the CAGR of 9.3% during the forecast period.
Industry Trends
The Europe induced pluripotent stem cell (iPSC) market has witnessed significant growth in recent years, driven by the increasing adoption The induced pluripotent stem cells (iPSCs) market in Europe is being driven by increasing adoption of stem cell therapy, which is being fueled by the growing biotechnology sector and investment opportunities. The rising prevalence of chronic diseases is also contributing to the growth of this market. Furthermore, the wide range of clinical applications of induced pluripotent stem cells and the emergence of technological advancements in iPSCs are anticipated to propel the market growth in Europe further.
Induced pluripotent stem cells (iPSCs) are derived from adult cells through reprogramming, resulting in pluripotent stem cells. These iPSCs possess similar characteristics to embryonic stem cells, enabling them to self-renew and differentiate into various cell types within the body, excluding those found in extra-embryonic tissues like the placenta. Induced pluripotent cells, which closely resemble the cell donor, play a crucial role in disease modeling. Retroviruses are frequently employed as carriers to reprogram induced pluripotent stem cells. The primary uses of induced pluripotent stem cells include disease modeling, drug discovery, toxicity testing, and gene therapy. These cells are extensively utilized in the treatment of cardiovascular diseases, diabetes mellitus, and different forms of cancer.
 Market.png)
To Understand More About this Research:Request a Free Sample Report
Induced pluripotent stem cells (iPSCs) have emerged as an ethical substitute for embryonic stem cells (ESCs). Their ability to transform into various cell types, including cardiomyocytes, has sparked hope in the medical community. The potential of differentiated cardiomyocytes in addressing heart failure, an area of research with limited alternatives, is a promising avenue that iPSCs are paving.
The increased interest in personalized medicine and the surge in healthcare expenditure are all factors that can contribute to the growth of this market. However, there are certain factors, such as the high cost associated with stem cell therapies and the availability of alternatives for tumor treatment, are some factors that are hindering the growth of the European induced pluripotent stem cells (iPSCs) market. The stringent rules and regulations surrounding iPSCs and the issue of genomic instability are key challenges faced by the Europe induced pluripotent stem cells (iPSCs) market.
Key Takeaways
- Germany dominated the market and contributed over 30% of the market share
- By derived cell category, the cardiomyocytes segment accounted for the largest Europe induced pluripotent stem cell (iPSC) market share in 2023
- By workflow category, the cell culture segment is dominant and is anticipated to grow with a lucrative CAGR over the Europe induced pluripotent stem cell (iPSC) market forecast period
What are the market drivers driving the demand for market?
Rising technological advancements drives the European induced pluripotent stem cell (iPSC) market growth.
The market is experiencing significant growth as the pluripotent stem cell models of development, regeneration, and disease are rapidly advancing. The continuous integration of new technologies and concepts with existing knowledge is leading to the creation of more realistic systems. These advancements, such as the use of iPSCs in regenerative medicine applications, disease modeling using iPSCs, iPSCs for drug discovery applications, and organoid models derived from iPSCs, are greatly improving our understanding of these complex processes. The potential of iPSC technology finds applications in regenerative therapy and human disease modeling for drug discovery purposes. In recent years, significant progress has been made in deriving various organ-specific cells and tissues from hPSCs, some of which have even advanced to clinical trials.
Which factor is restraining the demand for market?
High cost and maintenance associated affects the European market growth.
The European market faces significant constraints due to the high expenses associated with maintaining induced pluripotent stem cells (iPSCs). The costs of obtaining specialized equipment, reagents, and trained personnel for iPSC culture and upkeep can be prohibitive, making it difficult for smaller research institutions and biotech startups to access. Moreover, the continuous expenses related to sustaining ideal culture conditions, such as media, growth factors, and culture substrates, add to the financial strain. These elevated costs act as obstacles to entry, impeding the widespread acceptance and advancement of iPSC-based research and therapeutic progress in the European market.
 Market info.png)
Report Segmentation
The market is primarily segmented based on derived cell, workflow, application, and country:
|
By Derived Cell |
By Workflow |
By Application |
By Country |
|
|
|
|
To Understand the Scope of this Report:Speak to Analyst
Category Wise Insights
By Derived Cell Insights
Based on derived cell analysis, the market is segmented into Hepatocytes, Fibroblasts, Neural Cells, Amniotic Cells, Cardiomyocytes, and Others. The cardiomyocyte segment dominated the market and is expected to grow with the fastest CAGR in Europe's Induced Pluripotent Stem Cell (iPSC) market due to its wide applications in the medical and healthcare sectors. iPSC-derived cardiomyocytes offer a promising pathway for differentiation. The generation of cardiomyocyte tissue, capable of stimulating heart contractions, presents opportunities for advancements in regenerative research, including transplantation, bioprinting, disease modeling, and cardiac patches. These studies indicate that iPSCs have the potential to serve as a viable alternative to ESCs in the field of cardiac regenerative medicine.
By Workflow Insights
Based on workflow analysis, the market has been segmented into Reprogramming, Cell Culture, Cell Characterization / Analysis, Engineering, and Others. The cell culture segment has dominated the market. It is expected to experience significant growth with a lucrative CAGR over the forecast period in Europe's Induced Pluripotent Stem Cell (iPSC) market owing to its wide applications and progress in stem cell research such as regenerative medicine, drug discovery, and toxicity testing. In regenerative medicine, induced stem cells offer promising opportunities for tissue engineering and transplantation therapies. In drug discovery, they provide valuable models for studying disease mechanisms, screening potential drug candidates and assessing the toxicity and safety profiles, ensuring compliance with regulations and patient safety.
 Market seg.png)
Country-wise Insights
Germany
Germany leads the Induced Pluripotent Stem Cell (iPSC) market in Europe since the country possesses a global technology hub with a strong emphasis on innovation and research and development. The widespread implementation of stem-cell treatments in Germany has resulted in a decrease in common diseases like coronary heart disease and infectious diseases. The utilization of human stem-cell lines has led to a 30% reduction in animal experiments for toxicological and pharmaceutical research. Germany benefits from ample public and private funding, a well-trained scientific workforce, effective technology transfer between academia and industry, access to national and international markets, strong social acceptance, transparent information availability, global collaborations, supportive political and legal structures, and comprehensive health insurance coverage.
Competitive Landscape
The competitive landscape for the European Induced Pluripotent Stem Cell (iPSC) market is characterized by information on competitors, market potential, research and development investments, new market strategies, production facilities and technology life cycle. These details specifically focus on the company's involvement in the iPSCs market. Key Players are striving to gain market share and differentiate themselves through innovation and strategic partnerships. Amidst this landscape, collaboration between technology vendors, scientists, and research and development remains crucial for driving innovation, expanding market reach, and addressing evolving customer demands
Some of the major players operating in the European market include:
- Axol Bioscience Ltd.
- Charles River Laboratories International, Inc.
- Corning Incorporated
- FUJIFILM Corporation
- Horizon Discovery Ltd.
- LumaCyte
- R & D Systems, Inc.
- REPROCELL Inc.
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
Recent Developments
- In January 2024, StemSight and ERS Genomics have recently announced a non-exclusive license agreement as they joined forces to develop stem cell-based therapies for corneal blindness.
- In August 2023, BlueRock Therapeutics and bit. bio have joined forces in a research collaboration. This collaboration utilizes bit. bio's cutting-edge machine learning-powered discovery platform to identify optimal combinations of transcription factors (TFs) for reprogramming induced pluripotent stem cells (iPSCs) into Tregs.
- In June 2023, KaryoLogic announced a collaboration with Stem Genomics from Montpellier, France. This partnership will enable KaryoLogic to provide a digital assay capable of detecting over 90% of the prevalent genomic abnormalities observed in human pluripotent stem cells, as stated by KaryoLogic.
Report Coverage
The Europe induced pluripotent stem cell (iPSC) market report emphasizes on key countries across the region to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the region. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, derived cell, workflow, application and their futuristic growth opportunities.
Europe Induced Pluripotent Stem Cell (iPSC) Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 546.24 million |
|
Revenue forecast in 2032 |
USD 1,111.97 million |
|
CAGR |
9.3% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2032 |
|
Segments covered |
By Derived Cell, By Workflow, By Application, By Country |
|
Regional scope |
UK, France, Germany, Italy, Spain, Netherlands, Russia, Rest of Europe |
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
The Europe Induced Pluripotent Stem Cell (iPSC) Market report covering key segments are derived cell, workflow, application, and country
Europe Induced Pluripotent Stem Cell (iPSC) Market Size Worth USD 1,111.97 Million By 2032
Europe Induced Pluripotent Stem Cell (iPSC) market exhibiting the CAGR of 9.3% during the forecast period.
key driving factors in Europe Induced Pluripotent Stem Cell (iPSC) Market are Rising technological advancements
